CF PharmTech, Inc. (2652) Announces Proposed Adoption of 2025 H Share Award Scheme

Bulletin Express

Yesterday

CF PharmTech, Inc. (長風藥業股份有限公司) (Stock Code: 2652) has resolved to propose the adoption of its 2025 H Share Award Scheme, seeking to enhance employee and management engagement by aligning their interests with shareholders. The proposed initiative is designed to reward contributions and foster long-term development.

The H Share Award Scheme involves the use of existing shares rather than issuing new securities. While it does not require shareholder approval under Chapter 17 of the Listing Rules, the company is subject to its own governance processes. Consequently, the scheme and related authorizations must be approved by shareholders at the general meeting.

Shareholder authorization will also be sought to grant the board or an authorized party the ability to manage all matters related to the scheme. Further details, including key terms of the H Share Award Scheme, will be provided in a circular distributed to shareholders in due course.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1193664454"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1193664454\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1193664454?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-13 07:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1193664454","market":"us","top_or_hot":-1,"title":"CF PharmTech, Inc. (2652) Announces Proposed Adoption of 2025 H Share Award Scheme","media":"Bulletin Express","content":"<p>CF PharmTech, Inc. (長風藥業股份有限公司) (Stock Code: 2652) has resolved to propose the adoption of its 2025 H Share Award Scheme, seeking to enhance employee and management engagement by aligning their interests with shareholders. The proposed initiative is designed to reward contributions and foster long-term development.</p>\n<p>The H Share Award Scheme involves the use of existing shares rather than issuing new securities. While it does not require shareholder approval under Chapter 17 of the Listing Rules, the company is subject to its own governance processes. Consequently, the scheme and related authorizations must be approved by shareholders at the general meeting.</p>\n<p>Shareholder authorization will also be sought to grant the board or an authorized party the ability to manage all matters related to the scheme. Further details, including key terms of the H Share Award Scheme, will be provided in a circular distributed to shareholders in due course.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CF PharmTech, Inc. (2652) Announces Proposed Adoption of 2025 H Share Award Scheme</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCF PharmTech, Inc. (2652) Announces Proposed Adoption of 2025 H Share Award Scheme\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2025-11-13 07:25</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CF PharmTech, Inc. (長風藥業股份有限公司) (Stock Code: 2652) has resolved to propose the adoption of its 2025 H Share Award Scheme, seeking to enhance employee and management engagement by aligning their interests with shareholders. The proposed initiative is designed to reward contributions and foster long-term development.</p>\n<p>The H Share Award Scheme involves the use of existing shares rather than issuing new securities. While it does not require shareholder approval under Chapter 17 of the Listing Rules, the company is subject to its own governance processes. Consequently, the scheme and related authorizations must be approved by shareholders at the general meeting.</p>\n<p>Shareholder authorization will also be sought to grant the board or an authorized party the ability to manage all matters related to the scheme. Further details, including key terms of the H Share Award Scheme, will be provided in a circular distributed to shareholders in due course.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02652","symbol_name":"长风药业","start_time":0,"source_url":"","article_id":"1193664454","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1193664454","pubTimestamp":1762989905,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"CF PharmTech, Inc. (長風藥業股份有限公司) (Stock Code: 2652) has resolved to propose the adoption of its 2025 H Share Award Scheme, seeking to enhance employee and management engagement by aligning their...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02652":"长风药业"},"translate_title":"CF PharmTech，Inc.(2652)公布建议采纳2025年H股奖励计划","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02652":1},"content_text":"CF PharmTech, Inc. (長風藥業股份有限公司) (Stock Code: 2652) has resolved to propose the adoption of its 2025 H Share Award Scheme, seeking to enhance employee and management engagement by aligning their interests with shareholders. The proposed initiative is designed to reward contributions and foster long-term development.\nThe H Share Award Scheme involves the use of existing shares rather than issuing new securities. While it does not require shareholder approval under Chapter 17 of the Listing Rules, the company is subject to its own governance processes. Consequently, the scheme and related authorizations must be approved by shareholders at the general meeting.\nShareholder authorization will also be sought to grant the board or an authorized party the ability to manage all matters related to the scheme. Further details, including key terms of the H Share Award Scheme, will be provided in a circular distributed to shareholders in due course.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}